Kurome Therapeutics Closes $15 Million Series A Financing To Develop Targeted Kinase Inhibitors For Treatment Of Hematopoietic Cancers

Jun 10, 2021•over 4 years ago

Amount Raised

$15 Million

Round Type

series a

Cincinnati

Description

Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.

Company Information

Company

Kurome Therapeutics

Location

Cincinnati, Ohio, United States

About

Kurome® Therapeutics is a preclinical stage company developing novel therapies that subvert cancer’s ability to evade treatment. Founded on research at Cincinnati Children’s Hospital Medical Center in collaboration with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), Kurome is developing a series of combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that have co-opted IRAK1/4-mediated immune signaling pathways to survive.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Kurome Therapeutics Closes $15 Million Series A Financing To Develop Targeted Kinase Inhibitors For Treatment Of Hematopoietic Cancers

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information